assessed the impact of semaglutide treatment (0.5 – 1 mg weekly) over 12 to 36 months on weight reduction and glycemic control in four adults with PWS with concomitant diabetes, all of whom also started growth hormone replacement approximately 3 to 5 years before semaglutide initiation. Here, GH1 is linked to Prader-Willi syndrome.